Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 815 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later... September 30, 2020 A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... May 9, 2023 Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients... May 7, 2026 FDA Approves New Interchangeable Biosimilar to Pertuzumab December 3, 2025 Load more HOT NEWS Workout Wednesdays – Chest Exercises Part 2 Coping With Cancer Recurrence: My Perspective As Both a Patient and... “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence...
